Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.
Saved in:
| Title: | Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. |
|---|---|
| Authors: | Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. motzerr@mskcc.org., Martini JF; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA., Mu XJ; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA., Staehler M; Department of Urology, University Hospital of Munich, Munich, Bavaria, 80333, Germany., George DJ; Department of Medicine, Duke Cancer Institute, Durham, NC, 27710, USA., Valota O; Global Product Development-Oncology, Pfizer S.r.L, Milan, Lombardy, 20152, Italy., Lin X; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA., Pandha HS; Department of Medical Oncology, University of Surrey, Guildford, England, GU2 7XS, UK., Ching KA; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA., Ravaud A; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, 33300, France. |
| Source: | Nature communications [Nat Commun] 2022 Oct 10; Vol. 13 (1), pp. 5959. Date of Electronic Publication: 2022 Oct 10. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-022-33555-8 |
